

RAF265

Catalog No: tcsc0232



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg



Specifications

CAS No:

927880-90-8

Formula:

$C_{24}H_{16}F_6N_6O$

Pathway:

Protein Tyrosine Kinase/RTK;MAPK/ERK Pathway;Autophagy

Target:

VEGFR;Raf;Autophagy

Purity / Grade:

>98%

Solubility:

DMSO : \geq 26 mg/mL (50.15 mM); Ethanol : 10 mg/mL (19.29 mM; Need ultrasonic)

Alternative Names:

CHIR-265

Observed Molecular Weight:

518.41

Product Description


RAF265 is a potent **RAF/VEGFR2** inhibitor.

IC50 & Target: RAF^[1]

VEGFR2^[1]

In Vitro: The MTT assay reveals that in HT29 and MDAMB231 cells, RAF265 alone shows significant activity with IC₂₀ values of 1 to 3 μM and IC₅₀ values of 5 to 10 μM. In A549 and HCT116 cells, IC₂₀ values are 1 μM for both, but RAF265 concentrations up to 10 μM do not reach IC₅₀ values. However, in the presence of 1 nM RAD001, the IC₅₀ for RAF265 is 5 μM in A549 cells and 10 μM in HCT116 cells^[1].

In Vivo: In single-compound efficacy studies, optimal dosing of RAD001 and RAF265 is 5 to 12 mg/kg daily and 30 mg/kg every two days, respectively. However, combination tolerability studies in nontumor-bearing mice define dose-limiting toxicity as a 10% weight loss with the combination of RAD001 at a dose of 12 mg/kg daily and RAF265 at a dose of 20 mg/kg every two days. Therefore, the combination of RAF265 at a dose of 12 mg/kg qd and RAD001 at a dose of 12 mg/kg qd seems to be the maximal tolerated dose. RAD001 and RAF265 are both given at a dose of 12 mg/kg qd, alone or concurrently, over 6 days. After a 2-day stop, the compounds are given for another 6 days, and the treatment is then stopped. To confirm the potential of the combination of RAF265 and RAD001, the antitumor effect of the combination is tested in HCT116 xenografts (*KRAS* mut, *PIK3CA* mut). In HCT116 xenografts, RAD001 or RAF265 given alone shows 60% to 65% and 71% to 72% TVI%, respectively^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!